<DOC>
	<DOCNO>NCT00020540</DOCNO>
	<brief_summary>RATIONALE : Biological therapy flt3L CD40-ligand use different way stimulate immune system stop cancer cell grow . Biological therapy may effective treatment metastatic melanoma metastatic kidney cancer . PURPOSE : Phase I trial study effectiveness flt3L combine CD40-ligand treat patient metastatic melanoma metastatic kidney cancer .</brief_summary>
	<brief_title>Biological Therapy Treating Patients With Metastatic Melanoma Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose CD40-ligand combine fixed-dose flt3 ligand patient metastatic melanoma renal cell cancer . OUTLINE : This dose-escalation study CD40-ligand . Patients receive fixed-dose flt3 ligand subcutaneously ( SC ) daily day 1-14 CD40-ligand SC daily day 12-16 . Treatment continue every 28 day maximum 6 course absence unacceptable toxicity disease progression . Cohorts 3 6 patient receive escalate dos CD40-ligand maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients progressive disease 2 course may eligible receive high-dose interleukin-2 ( IL-2 ) standard therapy . PROJECTED ACCRUAL : A total 5 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Flt3 ligand protein</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic renal cell cancer melanoma Measurable disease PATIENT CHARACTERISTICS : Age : 16 Performance status : ECOG 01 Life expectancy : More 3 month Hematopoietic : WBC least 3,000/mm3 Platelet count least 90,000/mm3 No coagulation disorder Hepatic : Bilirubin great 1.6 mg/dL AST ALT less 2.5 time normal Hepatitis B surface antigen negative Renal : Creatinine great 2.0 mg/dL Cardiovascular : No major active medical illness cardiovascular system ( e.g. , cardiac ischemia , myocardial infarction , cardiac arrhythmia ) Pulmonary : No major active medical illness respiratory system ( e.g. , obstructive restrictive pulmonary disease ) Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active systemic infection No history autoimmune disorder HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior biologic therapy No prior systemic flt3 ligand CD40ligand Chemotherapy : At least 3 week since prior chemotherapy Endocrine therapy : At least 3 week since prior endocrine therapy No concurrent systemic steroid Radiotherapy : Prior localize radiotherapy renal cell cancer melanoma allow Surgery : Prior surgery renal cell cancer melanoma allow</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2002</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>